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Frequent binge drinking has been linked to heart disease, high blood pressure, type 2 diabetes, and the development of ethanol
dependence. Thus, identifying pharmaceutical targets to treat binge drinking is of paramount importance. Here we employed a mouse
model of binge-like ethanol drinking to study the role of neuropeptide Y (NPY). To this end, the present set of studies utilized
pharmacological manipulation of NPY signaling, immunoreactivity (IR) mapping of NPY and NPY receptors, and electrophysiological
recordings from slice preparations of the amygdala. The results indicated that central infusion of NPY, a NPY Y1 receptor (Y1R) agonist,
and a Y2R antagonist significantly blunted binge-like ethanol drinking in C57BL/6J mice (that achieved blood ethanol levels 480 mg/dl in
control conditions). Binge-like ethanol drinking reduced NPY and Y1R IR in the central nucleus of the amygdala (CeA), and 24 h of
ethanol abstinence after a history of binge-like drinking promoted increases of Y1R and Y2R IR. Electrophysiological recordings of slice
preparations from the CeA showed that binge-like ethanol drinking augmented the ability of NPY to inhibit GABAergic transmission.
Thus, binge-like ethanol drinking in C57BL/6J mice promoted alterations of NPY signaling in the CeA, and administration of exogenous
NPY compounds protected against binge-like drinking. The current data suggest that Y1R agonists and Y2R antagonists may be useful for
curbing and/or preventing binge drinking, protecting vulnerable individuals from progressing to the point of ethanol dependence.
Neuropsychopharmacology (2012) 37, 1409–1421; doi:10.1038/npp.2011.327; published online 4 January 2012


















































Alcohol (ethanol) dependence and relapse in abstinent
alcoholics are major health problems in the United States,
and neurochemical pathways that modulate these disorders
are currently under investigation. However, the central
mechanisms involved in the regulation of binge alcohol
drinking, before the development of dependence, have
received far less attention. As with all patterns of alcohol
abuse, frequent binge drinking is associated with numerous
negative short- and long-term consequences including
increased risk of accidental injury (Gmel et al,
2006), increased mood disorders (Okoro et al, 2004), and
increased aggressive and violent behavior (Shepherd et al,
2006). Perhaps most alarming is the finding of increased
risk for developing alcohol dependence in individuals that
binge drink early in life (Hingson et al, 2005, 2006; Miller
et al, 2007). Thus, it is of paramount importance to identify
neurochemical pathways in the brain that modulate binge
drinking as such knowledge will provide insight into novel
pharmaceutical treatments that will protect against this
dangerous behavior.
The ‘drinking in the dark’ (DID) procedure is a well-
established animal model of human binge drinking and has
been used to identify neurochemical modulators of binge-
like ethanol consumption (Gupta et al, 2008; Hendrickson
et al, 2009; Kamdar et al, 2007; Kaur and Ryabinin, 2010;
Linsenbardt and Boehm, 2009; Melon and Boehm, 2011;
Moore and Boehm, 2009; Sajja and Rahman, 2011). We have
recently found that corticotropin-releasing factor (CRF)
type-1 receptor (CRF1R) antagonists reduce binge-like
ethanol intake in C57BL/6J mice but fail to alter non-
binge-like (low level) ethanol intake (Lowery et al, 2010;
Sparta et al, 2008). These observations are strikingly similar
to evidence showing that CRF1R antagonists protect against
excessive dependence-like ethanol drinking in ethanol
vapor-exposed rats but fail to alter normal ethanol drinking
in nondependent animals (Finn et al, 2007; Funk et al, 2006;
Gehlert et al, 2007; Valdez et al, 2002). As with CRF1R
antagonists, central administration of neuropeptide Y
(NPY) has also been shown to protect against excessive
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dependence-like ethanol drinking in outbred rats exposed
to ethanol vapor without influencing normal ethanol intake
in nondependent animals (Gilpin et al, 2008). Furthermore,
although the effects of NPY on binge-like ethanol drinking
have not been reported, we have previously found that
central administration of a range of NPY doses failed to
alter low non-binge-like ethanol drinking in C57BL/6J mice
(Thiele et al, 2003), analogous to the inability of NPY to
blunt low-level ethanol intake in rats not exposed to ethanol
vapor. Interestingly, central administration of NPY pro-
tected against excessive ethanol drinking in rats selectively
bred for high ethanol intake but failed to alter ethanol
drinking in rats selected for low ethanol intake (Badia-Elder
et al, 2001, 2003), consistent with a selective role for NPY
in modulating excessive ethanol consumption. Central NPY
acts through three receptor subtypes, namely the Y1
receptor (Y1R), Y2R, and Y5R, all of which couple to G
proteins that inhibit production of cyclic AMP (cAMP)
(Palmiter et al, 1998). The Y1R is located postsynaptically
and NPY signaling via the Y1R protects against ethanol
intake (Naveilhan et al, 1998; Thiele et al, 2002). The Y2R
is primarily located presynaptically where it acts as an
autoreceptor to inhibit release of endogenous NPY and as a
heteroreceptor that inhibits the release of glutamate and
GABA (King et al, 2000; Qian et al, 1997; Smith-White et al,
2001; Wahlestedt et al, 1986). Consistent with a role as an
autoreceptor, a Y2R antagonist was found to reduce ethanol
intake, presumably by increasing endogenous NPY signal-
ing (Thorsell et al, 2002).
In light of the parallel observations that NPY and
CRF1R antagonist protect against excessive dependence-
like ethanol drinking without altering normal ethanol intake
in nondependent rodents, and the recent observations
that CRF1R antagonists protect against binge-like ethanol
drinking (Lowery et al, 2010; Sparta et al, 2008), the main
goal of the present set of experiments was to determine if
NPY, like CRF1R antagonists, would attenuate binge-like
ethanol drinking. Here we show that centrally administered
NPY, a Y1R agonist, and a Y2R antagonist protected against
binge-like ethanol drinking in C57BL/6J mice. Furthermore,
a history of binge-like ethanol drinking was associated with
a significant reduction of NPY and Y1R immunoreactivity
(IR) in the central nucleus of the amygdala (CeA), whereas
24 h without ethanol access following binge-like ethanol
drinking was associated with a significant increase of
Y1R and Y2R IR in the CeA. Using whole-cell recordings
from tissue slice preparations, we found that NPY-induced
inhibition of GABAergic transmission was augmented in the
CeA of mice with a history of binge-like drinking. Together,
the current findings show that NPY signaling modulates
excessive binge-like ethanol intake.
MATERIALS AND METHODS
Animals
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME)
were used in all experiments. Mice were B8 weeks of age,
weighed between 25 and 30 g, and were housed as
previously described (Lowery et al, 2010). Experiments
were approved by the University of North Carolina Animal
Care and Use Committee and complied with the NIH Guide
for Care and Use of Laboratory Animals.
DID Procedures
A 4-day DID procedure was used in all experiments
(Rhodes et al, 2005). On days 1–3, beginning 2.75 h into
the dark cycle, water bottles were removed from all cages. For
all experiments involving intracerebroventricular (i.c.v.)
administration of compounds, animals were weighed and
infused with sterile water or isotonic saline (1ml) to habituate
them to infusion procedures on days 1–3. Beginning 3 h into
the dark cycle, bottles containing 20% ethanol (v/v) were
weighed and placed on cages for 2 h. The same schedule was
followed on day 4 except that i.c.v. infusion of drug was
given just before ethanol access (which was extended to 4 h).
Immediately after ethanol access, tail blood samples (15ml)
were collected for analysis of blood ethanol concentrations
(BECs; Analox Blood Analyzer, Analox Instruments USA,
Lunenburg, MA). Two separate studies (NPY and Y1R
antagonist infusion studies) used Latin Square designs in
which mice experienced each dose of drug in a counter-
balanced order (1 DID cycle per dose). The remaining
i.c.v. infusion studies used a single-dose exposure design
(1 DID cycle per experiment). Additional control studies
were performed in which mice were given access to 10%
(pharmacology studies) or 3% (immunohistochemistry
studies) sucrose (w/v) in the same pattern as 20% ethanol
using DID procedures. A lower concentration of sucrose
was used in immunohistochemistry studies in an attempt to
avoid potential weight gain by mice stemming from
6 weeks of access to sucrose. For the IR study (below),
separate groups of mice experienced 1, 3, or 6 four-day
DID cycles.
Surgery and Infusion Procedures
Approximately 1 week after arrival, mice underwent surgery
to implant cannulae aimed at the lateral ventricle as des-
cribed previously (Lowery et al, 2010). Mice were allowed to
recover B1 week before experimental procedures were
started. Cannula placement was verified histologically at the
end of the experiment.
Drugs
The i.c.v. infusions were given manually in a 1.0ml volume
over a 1-min period with a 1.0ml Hamilton microsyringe. The
following compounds were used: NPY (0, 1, 3, or 10mg/ml;
Phoenix Pharmaceuticals, Burlingame, CA), the selective Y1R
agonist [D-His26]-NPY (0, 1, or 3mg/ml; American Peptide,
Sunnyvale, CA), the selective Y1R antagonist BIBP-3226
(0, 0.01, or 0.1mg/ml; Tocris Bioscience, Ellisville, MO), the
selective Y2R agonist NPY1336 (0, 1, 3, or 10mg/ml, Phoenix
Pharmaceuticals), and the selective Y2R antagonist BIIE-0246
(0, 1, or 3mg/ml, Tocris Bioscience). The [D-His26]-NPY
has been shown to be 90-fold selective for the Y1R vs the
Y2R, and 376-fold selective for the Y1R vs the Y5R (Mullins
et al, 2001). BIBP-3226 was shown to have almost no affinity
at NPY receptors other than the Y1R receptor (Doods et al,
1996). NPY1336 is 136-fold more selective for the Y2R vs
the Y1R, and is 10-fold more selective for the Y2R vs the
NPY receptor signaling and binge-like drinking
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Y5R (Gerald et al, 1996). BIIE-0246 has almost no affinity
for the Y1R and Y5R (Doods et al, 1999). Doses appropriate
for i.c.v. administration were based on previous research
(Bacchi et al, 2006; Nakhate et al, 2009; Sorensen et al, 2004).
Effects of Binge-Like Ethanol Drinking on NPY, Y1R,
and Y2R IR
To control for age between groups that experienced 1–6
cycles of binge-like drinking (described above), the initia-
tion of binge-like drinking was staggered such that all
mice experienced their last binge-like drinking cycle at the
same age. A control group drank water only throughout
the duration of the experiment. Immediately after their last
binge-like drinking session, blood samples were collected
and mice were anesthetized with a ketamine (117 mg/kg)
and xylazine (7.92 mg/kg) cocktail. Within 5 min of
anesthesia injection, mice were then transcardially perfused
with 0.1 mM of phosphate-buffered saline (PBS, pH 7.4)
followed by 4% paraformaldehyde in buffered saline. Brains
were collected and postfixed for 48 h in paraformaldehyde at
4 1C and then transferred to PBS until slicing. For compar-
ison with data collected from electrophysiological analyses
(see below), an additional set of mice that experienced three
binge-like drinking cycles with 20% ethanol were anesthe-
tized and perfused B24 h after their last binge-like drinking
session (blood samples were collected immediately after
the last drinking session). The whole brain was sliced into
40mm sections using a Leica VT 1000S vibratome (Leica
Microsystems, Nussloch, Germany) and stored in a cryo-
preserve solution until IR analysis. The sections were cut
into three sets and processed with antibodies raised against
NPY (Phoenix Pharmaceuticals; 1 : 1000; Thiele et al, 2000),
Y1R (Antibody 96106 raised against NPY Y1R
was provided by CURE/Digestive Disease Research Center,
Antibody/RIA Core, NIH grant DK41301 (Los Angeles, CA);
1 : 25 000; Lyons and Thiele, 2010), or Y2R (Neuromics,
Edina, MN; 1 : 4000). Tissues from all experimental groups
were run through each assay at the same time for each
antibody tested. It has previously been shown that the
Y1R (Kopp et al, 2002) and Y2R (Brumovsky et al, 2005)
antibodies do not react in knockout mice, verifying the
selectively of these antibodies. Specificity of the NPY
antibody was verified with colocalization of green fluor-
escent protein (GFP) and NPY (495%) in NPY-sappphire-
GFP transgenic mice (Pinto et al, 2004). NPY and Y1R IR
were visualized using standard 3,30-diamino-benzidine
(DAB) procedures that we have described previously (Hayes
et al, 2005; Lyons and Thiele, 2010; Navarro et al, 2008).
Because Y2R IR is less easily detected, sections for Y2R IR
underwent an amplification procedure using a Tyramide
Signal Amplification (TSA) detection kit (Jackson Labora-
tories) to increase signal sensitivity. For the Y2R assay, we
used different procedures than used with the NPY and Y1R
antibodies, which were based on procedures previously used
with the Y2R antibody utilized here (Brumovsky et al, 2005).
For NPY and Y1R IR, digital pictures of candidate brain
regions were obtained using a Nikon E400 microscope ( 20
objective) with a Nikon Digital Sight DS-U1 digital camera
run with Nikon provided software. For Y2R IR, images of
candidate brain regions were obtained using a Leica SP2
upright confocal microscope with 10 objective and Leica
Confocal Software. Anatomical landmarks were carefully
noted with the aid of a mouse brain atlas (Franklin and
Paxinos, 1997) to ensure the same plane was used
throughout the study for each region. Density staining were
analyzed by a researcher blind to conditions using Image J
Software (Image J, National Institute of Health, Bethesda,
MD) by calculating the percentage of the total area studied
that showed staining relative to subthreshold background.
The size of the area was held constant between animals and
groups for each region. The average of the densities for the
left and right sides of the brain was calculated for analysis.
Counts of NPY cell bodies, in the same area of the CeA used
to quantify average densities, were scored by a group-
blinded researcher (and average counts from the left and
right sides were averaged for analysis).
Effects of Binge-Like Ethanol Drinking on NPY-Induced
Inhibition of GABAergic Transmission in the CeA
Male C57BL/6J mice experienced three cycles of binge-like
drinking with 20% (v/v) ethanol as described above. A
control group of mice had access to only water throughout
the experiment. At B24 h after the last binge-like drinking
session, mice were decapitated and their brains were rapidly
removed. Slice preparations of the CeA were carefully
prepared and whole-cell recordings were performed as
previously described (Kash and Winder, 2006). Briefly,
GABAA-IPSCs were pharmacologically isolated by adding
10mM NBQX. Signals were acquired via a Multiclamp 700B
amplifier (Axon Instruments, Sunnyvale, CA), digitized, and
analyzed via pClamp 10.2 software (Axon Instruments). Input
resistance and series resistance were continuously monitored
during experiments. Experiments in which changes in series
resistance were 420% were not included in the data analysis.
eIPSC experiments were analyzed by measuring the peak
amplitude of the synaptic response, which was normalized to
the baseline period. Data were analyzed as mean eIPSC peak
amplitude over the course of the 20 min of recording and
were converted as the proportion of baseline eIPSC and as the
mean change of peak amplitude of eIPSC after the application
of NPY relative to pre-NPY levels.
Statistical Analyses
For all experiments, differences between groups were
analyzed using analysis of variance (ANOVA) or Student’s
t-tests. When significant differences were found, a post-hoc
analysis was performed using Tukey’s HSD test. Planned
comparisons were performed using Student’s t-tests. In all
cases, po0.05 (two tailed) was used to indicate statistical
significance. For BEC measures and IR data, in some cases,
data were not available for 1 to 2 animals; this accounts for
occasional differences in degrees of freedom between
similar analyses.
RESULTS
Effects of Centrally Administered NPY Compounds on
Binge-Like Ethanol Drinking
Intracerebroventricular administration of NPY. The 3 and
10 mg doses of NPY significantly blunted binge-like ethanol
NPY receptor signaling and binge-like drinking
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drinking and associated BECs (Figure 1a and b). Two-way
(cycles dose) ANOVAs were used to analyze the Latin
Square data. For drinking data, there was a significant main
effect of dose (F(3, 127)¼ 3.600; p¼ 0.015), but neither the
effect of binge drinking cycle (F(3, 127)¼ 1.082; p¼ 0.359)
nor interaction between variables (F(9, 127)¼ 1.234;
p¼ 0.280) differed significantly. For BEC data, a two-way
ANOVA revealed a significant main effect of dose
(F(3, 126)¼ 2.730; p¼ 0.047), but neither the effect of binge
drinking cycle (F(3, 126)¼ 1.028; p¼ 0.383) nor the inter-
action between variables (F(9, 126)¼ 1.216; p¼ 0.291)
achieved statistical significance. The post-hoc tests con-
firmed specific group differences. To determine if the effects
of NPY were specific to ethanol intake, a control study was
performed in which mice consumed a 10% (w/v) sucrose
solution. A group of mice that received a 3 mg dose of NPY
(n¼ 20) was compared with vehicle-treated mice (n¼ 19).
Relative to the vehicle condition (207.78±15.23 ml/kg), the
3 mg dose of NPY did not significantly alter sucrose intake
(182.18±16.79 ml/kg), evidenced by a nonsignificant one-
way ANOVA (F(1, 37)¼ 1.267; p¼ 0.268).
Intracerebroventricular administration of selective Y1R
compounds. Having demonstrated that central NPY can
selectively alter binge-like ethanol drinking, we next probed
the roles of individual NPY receptors. We found that
infusion of both 1 and 3 mg doses of the selective Y1R ago-
nist, [D-His26]-NPY, significantly blunted binge-like ethanol
drinking relative to the vehicle condition (Figure 1c;
F(2, 24)¼ 3.835; p¼ 0.036). However, relative to the vehicle
condition (212.43±13.88 mg/dl), mice treated with the 1mg
(166.20±29.39 mg/dl) and 3 mg (149.80±16.32 mg/dl) doses
of [D-His26]-NPY did not show significantly altered BECs
(F(2, 24)¼ 2.392; p¼ 0.113). Importantly, relative to the
Figure 1 NPY significantly blunted binge-like 20% ethanol consumption. (a) Central infusion (i.c.v.) of NPY dose-dependently reduced binge-like ethanol
consumption (g/kg per 4 h) and (b) associated BECs (mg/dl; n¼ 32–38 per group). NPY modulates binge-like consumption of 20% ethanol via NPY Y1R
activation and Y2R inactivation. (c) The i.c.v. infusion of the Y1R agonist [D-His26]-NPY significantly reduced binge-like ethanol consumption (g/kg per 4 h;
n¼ 9 per group). (d) The i.c.v. infusion of the Y1R antagonist BIBP-3226 significantly enhanced binge-like ethanol consumption (n¼ 24–28 per group).
(e) The i.c.v. infusion of the Y2R agonist NPY1336 did not alter binge-like ethanol consumption (n¼ 7–10 per group), (f) but i.c.v. infusion of the Y2R
antagonist BIIE-0246 significantly reduced binge-like ethanol consumption (n¼ 8–10 per group). For each compound, i.c.v. infusions were given on day 4 of
the 4-day binge-like drinking cycle. The NPY and BIBP-3226 infusion studies involved Latin Square designs in which mice experienced the various doses of
compound over multiple binge-like drinking cycles. All data are shown as mean±SEM, and significance was accepted at the po0.05 level (two tailed).
*Significant differences from vehicle.
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vehicle condition (n¼ 19, intake¼ 147.23±21.31 ml/kg)
both a 1 mg (n¼ 10, intake¼ 225.46±12.95 ml/kg) and
3 mg (n¼ 10, intake¼ 241.97±11.40 ml/kg) dose of
[D-His26]-NPY increased consumption of a 10% sucrose
solution, opposite to effects on binge-like ethanol drinking
(F(2, 36)¼ 7.340; p¼ 0.002). It is interesting that NPY
(above) did not alter sucrose drinking, yet the selective
Y1R agonist significantly increased sucrose drinking. The
observation that Y1R and Y2R signaling have opposing
effects on caloric intake (Feletou and Levens, 2005) may
account for the ability of the selective Y1R agonist to more
effectively stimulate sucrose drinking in our paradigm.
In order to determine if endogenous Y1R signaling
regulates binge-like ethanol drinking, we next examined
the impact of central infusion of the selective Y1R anta-
gonist, BIBP-3226 (Figure 1d). Two-way (cycles dose)
ANOVAs were used to analyze the Latin Square data. For
drinking data, there was a significant main effect of dose
(F(2, 68)¼ 3.379; p¼ 0.040), but neither the main effect of
binge drinking cycle (F(2, 68)¼ 1.066; p¼ 0.350) nor interac-
tion between variables (F(4, 68)¼ 1.027; p¼ 0.780) differed
significantly. However, there were no significant differences
in BECs between the vehicle group (79.54±14.15 mg/dl) and
the groups treated with the 0.01mg (109.70±15.77 mg/dl) and
0.1mg (114.01±14.62 mg/dl) doses of the Y1R antagonist.
A two-way ANOVA performed on BEC data showed that the
main effect of dose (F(2, 63)¼ 1.163; p¼ 0.319), the main
effect of binge drinking cycle (F(2, 63)¼ 1.937; p¼ 0.153),
and the interaction between variables (F(4, 63)¼ 1.064;
p¼ 0.382) all failed to achieve statistical significance. Relative
to mice treated with vehicle (n¼ 20, intake¼ 131.63±
12.76 ml/kg) mice treated with a 0.01mg dose of BIBP-3226
(n¼ 20, intake¼ 129.04±16.54 ml/kg) did not show altered
consumption of a 10% sucrose solution (F(1, 38)¼ 0.015;
p¼ 0.902).
Intracerebroventricular administration of selective Y2R
compounds. We next evaluated the role of the Y2R in binge-
like ethanol drinking. We found that i.c.v. infusion of
a range of concentrations of the selective Y2R agonist
NPY1336 did not significantly alter binge-like ethanol
drinking (Figure 1e; F(3, 32)¼ 0.848; p¼ 0.478)) or corres-
ponding BECs (data not shown). Relative to vehicle-
treated mice (n¼ 12, intake¼ 212.41±24.58 ml/kg), groups
treated with the 3 mg (n¼ 12, intake¼ 141.88±19.43 ml/kg)
and 10 mg (n¼ 12, intake¼ 132.04±22.38 ml/kg) doses of
NPY1336 drank significantly less of a 10% sucrose solution
(F(2, 33)¼ 3.887; p¼ 0.030), confirming that the doses of
the Y2R agonist that we used were in a physiologically
relevant range. In contrast, we found that i.c.v. infusion of
a 1 mg dose of the selective Y2R antagonist BIIE-0246
significantly blunted binge-like ethanol intake relative to
controls (Figure 1f; F(2, 24)¼ 3.766; p¼ 0.039). Further-
more, relative to vehicle treatment (84.57±26.55 mg/dl), the
0.5 mg (36.04±13.75 mg/dl) and 1 mg (21.69±5.82 mg/dl)
doses of the Y2R antagonist were associated with signifi-
cantly reduced BECs (F(2, 24)¼ 3.651; p¼ 0.043). Relative
to a vehicle-treated group (n¼ 11, intake¼ 156.10±
32.15 ml/kg), a group treated with a 1 mg dose of BIIE-
0246 (n¼ 12, intake¼ 156.10±32.15 ml/kg) did not show
altered consumption of a 10% sucrose solution (F(1, 21)¼
0.003; p¼ 0.954). It is interesting to note that the selective
Y2R agonist reduced sucrose drinking without influencing
ethanol intake, whereas the Y2R antagonist reduced ethanol
drinking but did not alter sucrose consumption. It is possi-
ble that the Y2R compounds may more efficiently reduce,
rather than increase, the high levels of intake characteristic
of our drinking procedures. As we would predict that the
Y2R agonist would, if anything, increase ethanol drinking,
and that the Y2R antagonist would increase sucrose
drinking, such effects may have been masked by the high
baseline levels of ethanol/sucrose consumption.
A couple of additional observations require considera-
tion. First, it should also be noted that baseline binge-like
ethanol drinking (in vehicle-treated groups) varied between
studies, but were within a range that we and others have
similarly observed using DID procedures (Bulwa et al, 2011;
Lowery et al, 2010; Sparta et al, 2008). Importantly, ethanol
intake levels within this range were associated with BEC
levels that were approximately at or above the BEC level
consistent with binge drinking (80 mg/dl). However, given
the baseline differences between studies, caution is neces-
sary when making between-study comparisons. Second,
in some experiments, compound-induced alterations of
ethanol intake were not associated with significant altera-
tions of BECs (although trends were always in the same
direction). This may be related to different patterns of
ethanol drinking over the 4 h test, perhaps stemming from
different durations of pharmacological action between the
different compounds in each study. It is also possible the
NPY-related compounds are less effective in reducing BEC
levels when baseline BECs are excessively high, as was the
case with the study that involved the selective Y1R agonist.
Effects of Binge-Like Ethanol Drinking on NPY, Y1R,
and Y2R IR
Having demonstrated that NPY, acting via Y1R and Y2R,
modulates binge-like ethanol drinking, we next examined
the impact of binge-like ethanol drinking on NPY, Y1R,
and Y2R IR in the CeA, a region shown to be involved
in dependence-like ethanol drinking (Gilpin et al, 2008). On
the final binge-like ethanol drinking session, there were no
significant differences between groups that experienced 1, 3,
or 6 cycles of binge-like drinking (n¼ 10/group) in terms of
the amount of ethanol consumed (4.867±0.161, 5.02±0.28,
and 5.13±0.274 g/kg, respectively) or BECs (112.94±10.50,
160.54±14.69, and 151.04±19.57 mg/dl, respectively). One-
way ANOVAs performed on both data sets failed to achieve
statistical significance.
NPY IR. NPY IR following repeated cycles of binge-like
drinking of 20% ethanol are presented in Figure 2a, and
representative photomicrographs of NPY IR from the CeA
of mice that drank water or experienced 1, 3, or 6 cycles of
binge-like ethanol drinking are presented in Figure 2b–e,
respectively. Relative to water (WAT) drinking control
mice, binge-like drinking of the 20% ethanol solution (1, 3,
or 6 cycles) was associated with a significant reduction of
NPY IR in the CeA, evidenced by a significant one-way
ANOVA performed on the data set (F(3, 36)¼ 57.551,
p¼ 0.001). However, relative to the WAT group (1.10±
0.049% area), a group of mice that experienced 1 cycle of
sucrose drinking (0.86±0.046% area) did not show
NPY receptor signaling and binge-like drinking
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significantly altered NPY IR. An ANOVA performed on
NPY-positive cell counts in the CeA (WAT¼ 6.4±0.562
average cells; 1 binge cycle¼ 5.8±0.611 average cells;
3 binge cycles¼ 4.6±0.957 average cells; 6 binge cycles¼
4.1±0.706 average cells) failed to achieve statistical signi-
ficance (F(3, 36)¼ 2.135, p¼ 0.113). These latter observa-
tions suggest that significant binge-like drinking-induced
reduction of NPY IR with densitometry reflects primarily a
reduction of NPY in terminal processes.
We also assessed the effects of binge-like ethanol drinking
on NPY IR in the BLA (WAT¼ 0.385±0.026% area; 1 binge
cycle¼ 0.369±0.035% area; 3 binge cycles¼ 0.396±0.027%
area; 6 binge cycles¼ 0.414±0.027% area) and in the
medial amygdala (MeA; WAT¼ 0.254±0.048% area; 1
binge cycle¼ 0.257±0.035% area; 3 binge cycles¼ 0.210±
0.012% area; 6 binge cycles¼ 0.172±0.012% area) and there
were no significant group differences in either region.
Representative photomicrographs of NPY IR in the BLA
from the WAT group and the group experiencing one cycle
of binge-like ethanol drinking are presented in Figure 4a
and b, respectively.
Y1R IR. Y1R IR following repeated cycles of binge-like
drinking of 20% ethanol is presented in Figure 3a, and
representative photomicrographs of Y1R IR from the CeA of
mice that experienced one cycle of binge-like ethanol
drinking or water control mice are presented in Figure 3b
and c, respectively. Binge-like drinking of the 20% ethanol
solution was associated with a significant reduction of Y1R
IR in the CeA, after 1, 3, or 6 binge-like drinking cycles,
when compared with the WAT group (F(3, 34)¼ 30.233,
p¼ 0.001). On the other hand, one cycle of binge-like
drinking of a 3% sucrose solution (0.11±0.019% area) did
not significantly alter Y1R IR in the CeA relative to the
WAT group (0.11±0.008% area). We assessed the effects
of binge-like ethanol drinking on Y1R IR in the BLA
(WAT¼ 0.055±0.007% area; 1 binge cycle¼ 0.052±0.004%
area; 3 binge cycles¼ 0.048±0.004% area; 6 binge cycles¼
0.056±0.007% area) and in the MeA (WAT¼ 0.062±
0.005% area; 1 binge cycle¼ 0.058±0.006% area; 3 binge
cycles¼ 0.081±0.009% area; 6 binge cycles¼ 0.065±
0.008% area), and there were no group differences in either
region. Representative photomicrographs of Y1R IR in the
Figure 2 Binge-like ethanol consumption of 20% ethanol significantly reduced NPY IR in the CeA. NPY IR (% total area) in the CeA after binge-like
drinking of ethanol (a), and representative photomicrographs depicting NPY IR in the CeA from mice that drank water (WAT) (b) or that experienced 1 (c),
3 (d), or 6 (e) cycles of binge-like ethanol drinking. There were n¼ 10 mice/group. All data are shown as mean±SEM, and significance was accepted at the
po0.05 level (two tailed). *Significant differences from the WAT group; #Significant differences from the WAT and one binge-like drinking cycle groups.
Images were captured at a magnification of  20, and the scale bar¼ 100 mm.
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BLA from the WAT group and the group experiencing one
cycle of binge-like ethanol drinking are presented in Figure
4c and d, respectively.
Y2R IR. Y2R IR following repeated cycles of binge-like
drinking of 20% ethanol is presented in Figure 5a, and
representative photomicrographs of Y2R IR from the CeA of
mice that experienced one cycle of binge-like ethanol
drinking or water control mice are presented in Figure 5b
and c, respectively. An ANOVA performed on Y2R IR data
was significant (F(2, 25)¼ 4.715, p¼ 0.0119). However,
post-hoc tests indicated that although neither binge-like
drinking group differed from the water control group, one
cycle of binge-like drinking of the 20% ethanol solution was
associated with a significant increase of Y2R IR in the CeA
when compared with the group that experienced three
binge-like drinking cycles. On the other hand, one cycle of
binge-like drinking of a 3% sucrose solution (122.74±
6.60% area) did not alter Y2R IR in the CeA relative to the
WAT group (109.39±2.72% area).
Effects of Binge-Like Ethanol Drinking on NPY-Induced
Inhibition of GABAergic Transmission in the CeA
We next evaluated the impact of three cycles of binge-
like ethanol drinking followed by 24 h without ethanol
access or continuous water drinking on NPY modulation of
GABAergic function in the CeA (Figure 6). The mice con-
sumed an average of 5.63±0.41, 6.06±0.31, and 5.27±
0.34 g/kg of ethanol on the final 4 h test day of each binge-
like drinking cycle, and showed average BECs of 131.91±
13.37 mg/dl when blood samples were collected immediately
after the final binge-like drinking session. Initially, we
examined the paired-pulse ratio (PPR) of eIPSCs in CeA
neurons. Alterations in this ratio are indicative of altera-
tions in the release of GABA, and previous experiments
have demonstrated that in vapor-exposed, dependent-like
animals, there is a reduced PPR in the CeA relative to
controls (Roberto et al, 2004). We found that there was no
difference in the PPR of eIPSCs in the CeA (Figure 6a).
Additionally, we measured the frequency (Figure 6b) and
the amplitude (Figure 6c) of spontaneous IPSCs, and found
no significant differences between the conditions. We next
evaluated the ability of 300 nM NPY to modulate GABAergic
transmission in the CeA. Representative traces are shown
demonstrating the effect of NPY on eIPSCs in the CeA
from water-exposed and binge-like ethanol drinking mice
(Figure 6d). The normalized average peak amplitude of
eIPSC depicted as percentage of baseline from slice prepara-
tions from the CeA are presented in Figure 6e. A two-way
(2 20), ethanol historymin repeated measures ANOVA
revealed significant main effects of min (F(19, 228)¼ 4.949,
p¼ 0.001), ethanol history (F(1, 12)¼ 4.274, p¼ 0.001), and
a significant interaction effect (F(19, 228)¼ 1.72, p¼ 0.034).
A t-test performed on eIPSC data represented as percent
change relative to baseline was significant (t(12)¼ 2.325,
p¼ 0.038; Figure 6f), and indicates that relative to the water
drinking control group, a history of binge-like ethanol
drinking was associated with a significant increase in NPY-
induced inhibition of GABAergic transmission in the CeA.
Because IR data described above were from mice that
were killed immediately after the final binge-like drinking
cycle, we also assessed NPY, Y1R, and Y2R IR in mice that
experienced three cycles of binge-like ethanol drinking
(or continuous water drinking) and were killed 24 h after
the last binge-like drinking session, similar to mice from
electrophysiological experiments. The mice consumed an
average of 5.37±0.31, 5.38±0.22, and 5.59±0.47 g/kg of
ethanol on the final 4 h test day of each binge-like drinking
cycle, and showed average BECs of 148.58±37.66 mg/dl
Figure 3 Binge-like ethanol consumption of 20% ethanol significantly
reduced Y1R IR in the CeA. Y1R IR (% total area) in the CeA after binge-
like drinking of ethanol (a), and representative photomicrographs depicting
Y1R IR in the CeA from mice that experienced one cycle of binge-like
ethanol drinking (b) or drank water (WAT) (c). There were n¼ 9–10 mice/
group. All data are shown as mean±SEM, and significance was accepted at
the po0.05 level (two tailed). *Significant differences from the WAT
group; #Significant differences from the WAT and one binge-like drinking
cycle groups. Images were captured at a magnification of  20 and the
scale bar¼ 100 mm.
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when blood samples were collected immediately after the
final binge-like drinking session. Relative to water drinking
control mice, mice with a history of three binge-like
drinking cycles and 24 h without ethanol access showed
a significant reduction of NPY IR in the CeA (Figure 7a;
t(14)¼ 2.417, p¼ 0.03), but significant increases of Y1R
(Figure 7b) and Y2R (Figure 7c) IR, confirmed by significant
t-tests (t(15)¼ 2.321, p¼ 0.035 and t(16)¼4.808, p¼ 0.001)
for Y1R and Y2R, respectively. An ANOVA performed on
NPY-positive cell counts in the CeA (WAT¼ 10.7±0.943
average cells; 3 binge cycles¼ 8.2±0.489 average cells)
achieved statistical significance (F(1, 18)¼ 5.531, p¼ 0.030).
Thus, blunted binge-like drinking-induced reduction of NPY
IR appears to have reflected both a reduction of NPY-positive
cell bodies and terminal processes. In Figure 8, representative
photomicrographs of the CeA (top row, NPY IR; middle row,
Y1R IR, and bottom row, Y2R IR) of mice that experienced
three cycles of binge-like ethanol drinking and 24 h without
ethanol access (Figure 8a, c, and e) or only drank water
(Figure 8b, d, and f) are presented.
DISCUSSION
This report provides novel evidence that NPY signaling
selectively modulates binge-like ethanol drinking in C57BL/
6J mice. Briefly, we found that i.c.v. infusion of NPY blunted
ethanol drinking associated with DID procedures. In addi-
tion, a Y1R agonist and a Y2R antagonist blunted binge-like
ethanol drinking, implicating the Y1R and Y2R as key
receptors in modulating this behavior. We then examined
the influence of a history of binge-like ethanol drinking on
NPY signaling in the CeA using immunohistochemistry and
electrophysiology approaches. In support of the behavioral
findings, we found that binge-like ethanol drinking reduced
NPY and Y1R IR in the CeA, and removal of ethanol for 24 h
following three cycles of binge-like ethanol drinking
promoted increases of Y1R and Y2R IR. Electrophysiologi-
cal recordings of slice preparations from the CeA showed
that binge-like ethanol drinking augmented the ability of
NPY to inhibit GABAergic transmission. Taken together,
the present observations (and previous data with CRF1R
antagonist; Lowery et al, 2010; Sparta et al, 2008) suggest
that signaling in critical NPY pathways is weakened (and
CRF signaling is enhanced) when sufficient amounts of
ethanol have been consumed during a binge-like drinking
episode, at which point administration of exogenous NPY
is effective in blunting binge-like ethanol intake (either by
restoring NPY signaling and/or by countering the effects of
CRF). Our previous finding that a range of centrally
administered NPY doses did not alter non-binge-like
ethanol drinking in C57BL/6J mice (Thiele et al, 2003)
suggests that NPY selectively modulates excessive ethanol
intake, which is also consistent with previous work on
dependence-like ethanol intake (Gilpin et al, 2008). Data
from immunohistochemistry and electrophysiology studies
point to the CeA as a critical brain region in which NPY
modulates binge-like drinking, and future studies that
directly manipulate NPY signaling in the CeA will help
address this question. Importantly, to the best of our
knowledge, these are the first observations of alterations of
NPY and NPY receptor signaling in animals voluntarily
drinking excessive amounts of ethanol, as previous work
has relied on forced ethanol exposure via ethanol vapor
(Criado et al, 2011; Ehlers et al, 1998; Gilpin et al, 2011;
Slawecki et al, 2005; Walker et al, 2010), ethanol-containing
Figure 4 Representative photomicrographs depicting NPY (a, b) and Y1R (c, d) IR in the BLA. Sections are from the group that drank water (a, c) or the
group the experienced one cycle of binge-like ethanol drinking (b, d). Scale bar¼ 100 mm.
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diet (Roy and Pandey, 2002; Zhang et al, 2010), or ethanol
injection (Pandey et al, 2008; Sakharkar et al, in press).
The effects of NPY on binge-like ethanol drinking appear
to be reciprocally modulated by Y1R and Y2R. Central
infusion of a selective Y1R agonist decreased, whereas a
selective Y1R antagonist increased, binge-like ethanol
intake. In contrast, central infusion of a selective Y2R
agonist did not significantly alter binge-like ethanol
drinking whereas central infusion of a selective Y2R anta-
gonist significantly decreased binge-like consumption.
Importantly, effective doses of selective NPY compounds
(and NPY) that altered binge-like ethanol drinking did not
influence 10% sucrose consumption in the same direction,
suggesting that the effects of these compounds were specific
to ethanol intake. Previous work has implicated roles for the
Y1R and Y2R in the modulation of ethanol consumption
(Thiele et al, 2002, 2004; Thorsell et al, 2002). The ability of
the Y1R antagonist to significantly increase binge-like
ethanol drinking suggests that Y1R signaling is engaged
during binge-like drinking episodes (perhaps early on in the
drinking episode); however, Y1R signaling in response to
Figure 5 Binge-like ethanol consumption of 20% ethanol did not
significantly alter Y2R IR relative to the water (WAT) control group, but
Y2R IR was significantly higher in the group that experienced one cycle of
binge-like drinking relative to the three cycle binge-like drinking group. Y2R
IR (% total area) in the CeA after binge-like drinking of ethanol (a), and
representative photomicrographs depicting Y2R IR in the CeA from a
mouse that experienced one cycle of binge-like ethanol drinking (b) or
drank WAT (c). There were n¼ 7–10 mice/group. All data are shown as
mean±SEM, and significance was accepted at the po0.05 level (two
tailed). #Significant differences from the group that experienced three
cycles of binge-like ethanol drinking. Images were captured at a
magnification of  10, the area within the white dashed line indicates
the region in which Y2R IR was quantified, and the scale bar¼ 200 mm.
Figure 6 A history of binge-like ethanol consumption significantly
facilitates NPY-induced inhibition of GABAergic transmission in the CeA
when assessed B24 h after removal of ethanol access in mice that
experienced three cycles of binge-like drinking of 20% ethanol. Binge-like
ethanol exposure did not alter paired-pulse ratio (a), sIPSC amplitude (b),
or sIPSC frequency (c) in the CeA. Representative traces from the water
(di) and binge-like ethanol-exposed mice (dii) demonstrate the impact of
exogenously applied NPY on eIPSCs. Scale bars represent 100 pA and
20 ms in each panel. Exogenous application of NPY in the CeA significantly
reduced eIPSC peak amplitudes (expressed as the mean proportion of
baseline) (e) and baseline peak amplitudes (f), an effect that was significantly
more robust in animals with a history of binge-like ethanol drinking relative
to water drinking animals (n¼ 6–8 per group). Baseline measures were
taken during 0–5 min, after which NPY (300 nM) was bath applied for 5–
15 min. All data are shown as mean±SEM, and significance was accepted at
the po0.05 level (two tailed). *Significant differences from the water
group.
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endogenous NPY is not sufficient to protect against binge-
like drinking, likely because of blunted NPY signaling that
develops over the course of the binge-like drinking episode
(see below). The ability of the Y2R antagonist to signi-
ficantly reduce binge-like ethanol drinking suggests that the
Y2R is also engaged during binge-like drinking. The Y2R
may be acting as an autoreceptor that reduces NPY release
(Chen et al, 1997; King et al, 1999), and thus blocking Y2R
would theoretically increase NPY signaling, upregulating
the protective effects of NPY.
We found that binge-like ethanol drinking lead to selec-
tive alterations to the NPY systems in the CeA, as sucrose
drinking did not alter NPY, Y1R, or Y2R IR. A lack of
influence of binge-like drinking on NPY or Y1R IR in the
BLA and MeA suggests that alterations of IR were specific to
the CeA. Although caution is necessary when inferring the
direction of changes in signaling based on IR data (Navarro
et al, 2008), when viewed together, the pharmacological and
IR data strongly suggest that over the course of a binge-like
drinking episode, endogenous NPY signaling is blunted,
which may motivate continued excessive binge-like drink-
ing. Low endogenous NPY signaling can be overcome by
administration of exogenous NPY or a selective Y1R
agonist, or a selective Y2R antagonist (which as a pre-
synaptic autoreceptor (Chen et al, 1997; King et al, 1999)
may increase endogenous NPY signaling). Interestingly,
chronic exposure to ethanol and withdrawal have been
reported to cause decreased levels of NPY in the amygdala
(Roy and Pandey, 2002; Zhang and Pandey, 2003), revealing
similar observations between paradigms promoting binge-
like drinking and dependence-like states in rodents.
Because data from the IR studies indicated an important
role for the CeA in the modulation of binge-like ethanol
drinking, we used in vitro slice electrophysiological proce-
dures to study the effects of binge-like ethanol drinking
on basal and NPY-induced alterations of GABAergic
transmission. We found no significant differences between
binge-like ethanol drinking and water control groups in
terms of PPR or spontaneous GABAergic transmission,
suggesting that a history of binge-like drinking did not alter
basal GABAergic function. This contrasts with previous
evidence indicating that baseline GABAergic transmission is
upregulated in the CeA of rats previously exposed to
ethanol vapor (Roberto et al, 2004), suggesting that on this
measure, the effects of a history of binge-like drinking are
different than the effects generated by models used to study
dependence-like ethanol drinking.
In tissue from mice that had a history of three cycles
of binge-like ethanol drinking and 24 h without ethanol
access, NPY-induced inhibition of GABA transmission was
enhanced, likely through activation of Y2R given the
established role of the Y2R in modulating the effects of
NPY on GABAergic transmission in the CeA (Gilpin et al,
2011). This finding was consistent with the IR results from
mice in which ethanol was removed for 24 h after three
cycles of binge-like ethanol drinking that also exhibited an
upregulation of Y2R (and Y1R) in the CeA relative to the
water drinking control group. When one considers the
potential autoreceptor function of the Y2R, these changes,
particularly the increase in Y2R IR, could be maladaptive,
potentially leading to reduced levels of both NPY release
and Y1R activation. Presynaptic Y2R also functions as a
heteroreceptor that inhibits GABA release (Qian et al, 1997),
which is the likely mechanism by which NPY inhibits
GABAergic release here and in previous reports (Gilpin
et al, 2011; Kash and Winder, 2006). When the heteroreceptor
function is considered, it is possible that NPY-mediated
inhibition of GABA release leads to increased excitability in
downstream populations of neurons. The functional rami-
fications of increased downstream excitability are difficult
to assess, as there are multiple populations of neurons in the
lateral CeA (Haubensak et al, 2010). The present electro-
physiology results complement the pharmacology and IR
data, which together strongly suggest that NPY signaling in
the CeA is compromised as a result of binge-like ethanol
drinking in C57BL/6J mice.
It was recently reported that application of NPY to slice
preparations from the CeA decreased baseline GABAergic
transmission and inhibited ethanol-induced stimulation
of GABAergic activity (Gilpin et al, 2011). Interestingly,
although we observed increased NPY-induced inhibition
of GABAergic activity in the CeA of mice with a history of
binge-like ethanol drinking, Gilpin et al (2011) found no
such differences between vapor-exposed and naive rats,
which is additional evidence that the mechanisms that drive
excessive ethanol intake in models of binge-like drinking
and dependence-like drinking are not identical. Although
we cannot rule out species differences as the cause of
discrepant results, one striking dissimilarity between our
study and that of Gilpin et al (2011) is that we studied
excessive ethanol intake in rodents that voluntarily drank
ethanol, whereas Gilpin et al (2011) studied excessive
ethanol intake in animals that had prior forced ethanol
exposure via vapor inhalation.
Importantly, Gilpin et al (2011) also found that prophy-
lactic application of NPY during ethanol vapor exposure
protected against the development of vapor-induced
ethanol drinking. These observations, in tandem with data
indicating that the direct application of NPY into the CeA
Figure 7 NPY IR (a), Y1R IR (b), and Y2R IR (c) (% total area) in mice
that experienced three cycles of binge-like drinking of 20% ethanol and
then 24 h without ethanol access or drank water (WAT) throughout the
study (n¼ 6–10 per group). All data are shown as mean±SEM, and
significance was accepted at the po0.05 level (two tailed). *Significant
differences from the WAT group.
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protects against vapor-induced dependence-like drinking
(Gilpin et al, 2008), further reinforce the hypothesis that the
dysregulation of NPY signaling in the CeA contributes
to uncontrolled and excessive ethanol intake (Koob, 2003;
Koob and Le Moal, 2001). We propose that a similar
(although not identical) dysregulation of NPY signaling
occurs within the CeA during the course of a binge-like
drinking episode. We speculate that blunted NPY signaling
that unfolds during the course of a binge can motivate
binge-like drinking in a manner similar to the role of
blunted NPY signaling in motivating vapor-induced depen-
dence-like drinking, and that dysregulation of NPY becomes
rigid with repeated binge episodes, contributing to the
transition to dependence. Viewed this way, in addition to
being potential pharmaceutical targets for treating excessive
ethanol intake resulting from dependence, the current data
suggest that NPY compounds (Y1R agonists and Y2R anta-
gonists) may also be useful for curbing and/or preventing
binge drinking, ultimately protecting vulnerable individuals
from progressing to the point of ethanol dependence.
Because neuroplastic changes that develop in the brain with
the development of dependence are thought to be long-
lasting and the underlying cause of uncontrolled excessive
ethanol intake characteristic of dependent individuals
(Koob, 2003; Koob and Le Moal, 2001), treating at-risk
individuals suffering from alcohol abuse disorders before
they have become dependent may be a more effective
approach than treatments that are aimed at individuals who
have already become dependent.
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Figure 8 Representative photomicrographs depicting IR of NPY (a, b), Y1R (c, d), and Y2R (e, f). The left columns (a, c, and e) are from mice that
experienced three cycles of binge-like ethanol drinking of 20% ethanol followed by 24 h without ethanol access, and the right columns (b, d, and f) are from
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